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ABSTRACT
Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is defined as a decline in hearing
affecting three or more frequencies by 30dB
Objective: The aim of this study was to evaluate the results of intratympanic steroids as a salvage
treatment for severe ISSNHL.
Materials and methods: A regimen of three IT steroid injections was offered to patients who failed a
7-days intravenous steroid treatment. Eighty-four patients underwent IT salvage treatment (IT group).
Their outcomes were compared with those of 255 patients with severe ISSNHL who received the same
intravenous steroid regimen without salvage IT steroid therapy (Control group).
Results: 56% of the patients in the IT group had a hearing improvement of >15dB after one month.
The average hearing improvements were 26.5 ±28dB and 27.9 ±24dB in the IT group and the Control
group, respectively (p¼ .67). However, patients with a type E audiogram pattern (total deafness), dis-
played a substantial hearing gain.
Conclusion: Intratympanic steroids failed to show a global auditory benefit as a salvage treatment in
patients with severe ISSNHL.
Significance: Our data suggest that a salvage treatment with intratympanic dexamethasone may be
offered to patients with total deafness for whom the first systemic treatment has failed.
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Introduction
Idiopathic sudden sensorineural hearing loss (ISSNHL) is
defined as a decline in hearing affecting three or more fre-
quencies by 30 dB or greater over 72 hours or less with no
identifiable etiology.
During 2006 and 2007, the annual incidence of ISSNHL
was 27 per 100,000 patients in the United States. The inci-
dence increased with increasing age, ranging from 11 per
100,000 for patients younger than 18 years to 77 per
100,000 for 65 years and older patients. There was an over-
all slight male preponderance with a male-to-female ratio of
1.07:1. This was more pronounced in patients 65 years and
older, with a ratio of 1.30:1 [1].
The etiology and natural history of ISSNHL are still
obscure. Many studies have assessed the percentage of spon-
taneous recovery in different curves; in 2014 Filipo et al.
published a spontaneous recovery in the flat curve of 25%
of patients [2]. However, the real number of patients that
recover spontaneously from ISSNHL is currently unknown,
as the true incidence of this disease is probably underesti-
mated because many who recover spontaneously within the
first days never seek medical therapy.
Various therapies are proposed without a universally
accepted standard protocol. Corticosteroids, antiviral agents,
vasodilators, hyperbaric oxygen therapy (HBOT), anticoagu-
lants, anti-inflammatory drugs, and other approaches have
been suggested alone or combined, with variable percentages
of efficacy reported in literature [3,4].
Currently, oral steroids are the most common choice of
treatment and are considered as the best treatment option
[5]. However, the use of intratympanic (IT) steroids has
become an attractive alternative [6]. On the basis of the
available literature, it seems that IT steroids can be a valu-
able solution for ISSNHL patients who cannot tolerate sys-
temic steroid therapy or when systemic therapy fails as first
line therapy [7].
The rationale for the efficacy of IT treatment entails a
mechanism of diffusion through the round window into the
cochlea, which has been described as following a tonotopy
from the base of the cochlea to its apex. Therefore, the
results of IT steroid therapy should be evaluated according
to each frequency change and not only according to pure
tone average. On the basis of this information, we designed
a study to address the efficacy of IT steroids for patients
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with severe ISSNHL after the failure of systemic treatment;
we used a large control group of patients with the same fea-
tures of severe-to-profound ISSNHL at one month.
Materials and methods
Study design
From September 1997 to September 2008, 550 patients,
male and female with severe-to-profound ISSNHL were
recruited by the ENT Emergency Room staff of the depart-
ment of a Lariboisiere hospital of Paris.
The diagnosis of severe-to-profound ISSNHL was based
on the following criteria: ISSNHL of at least 30 dB at three
or more consecutive frequencies in fewer than three days,
unilateral hearing loss, no history of treatment at another
center, no identified etiological factors to explain the hear-
ing loss, no history of a previous otologic disease or oper-
ation on the affected ear, no history of previous
chemotherapy or radiotherapy, and admission for first-line
therapy within 30 days after the onset of hearing loss. All
patients were treated with primary steroid therapy that con-
sisted of 1mg/kg/d dexamethasone (DXM) administration
intravenously for seven days. Three hundred and thirty-nine
(339) patients, 206 male and 133 female, with severe unilat-
eral ISSNHL did not respond to primary therapy with sys-
temic steroids. Failure to respond was defined as an
improvement in the pure tone average (PTA at 500, 1000,
2000, and 4000Hz) of less than 20 dB on day seven after the
conclusion of primary therapy. These patients were divided
into two groups to evaluate the efficacy of IT salvage ther-
apy: The first group consisted of 84 patients who received
IT salvage therapy (IT group) and the second group con-
sisted of 255 patients who did not receive IT therapy (con-
trol group). The initial evaluation patterns of ISSNHL were
classified into five subgroups according to the following
audiogram shapes: low tone (type A), flat (type B), high
tone (type C), cup-shaped (type D), and total or subtotal
(type E) (Figure. 1). The two groups were compared
and analyzed.
Standard assessment
The standard assessment included tonal combined with sta-
pedial reflex recording and vestibular caloric testing.
Laboratory tests included a complete blood cell count, a
coagulation profile, and blood glucose and lipid level tests.
Auto-immune testing and virus serological evaluation were
performed only in cases where herpes virus infection was
suspected. Magnetic Resonance Imagery (MRI), including
diffusion-weighted and FLAIR T2 sequences on the cerebral
parenchyma as well as slice thickness T2-weighted MRI
sequences on the internal auditory canals, was performed
between days two and 30 after the onset of ISSNHL.
Inclusion criteria were (1) sensorineural hearing loss
developed within 24 hours with a mean pure-tone audio-
gram with a minimum 60 dB loss on three subsequent fre-
quencies; no improvement after conventional therapy (2) no
marked vestibular symptoms (i.e. without nystagmus or ver-
tigo), and (3) no clinically identifiable causes.
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232Figure 1. The five types of SNHL according to their audiogram shape. Type A: low tone; Type B: flat; Type C: high tone; Type D: cup-shaped; Type E: total
or subtotal.
2 E. COVELLI ET AL.
Procedures
Intravenous treatment
All patients included in this study received an initial intra-
venous steroid regimen during hospitalization. The protocol
included a 7-day course of intravenous steroids (dexametha-
sone 1mg/kg/d) that was administered to every patient.
Intratympanic steroid treatment
The patient was offered IT steroid therapy in case of add-
itional hearing deterioration or in the absence of recovery,
which were defined as the absence of improvement of at
least 20 dB in PTA at the last day of i.v. steroid treatment.
Eighty-four patients agreed to receive this treatment, which
was delivered as an outpatient procedure. The therapeutic
protocol for IT administration consisted in three sessions of
IT injection of dexamethasone (DXM), carried out within a
10-day period. The IT steroid treatment consisted of 2mL
of a sterile aqueous suspension of dexamethasone at a con-
centration of 4mg/mL. The patients lay in the supine pos-
ition with their heads tilted 45 towards the opposite ear.
The procedure was performed under a microscope. After
confirmation of an intact tympanic membrane, local anes-
thesia was achieved via topical application of lidocaine and
prilocaine in the external auditory canal for 20minutes.
Once the lidocaine and prilocaine were removed, a 25-gauge
spinal needle and 2mL syringe were used to puncture the
postero-inferior quadrant of the tympanic membrane.
Through the myringotomy, 1mL of DXM (4mg/mL) was
slowly injected to perfuse the middle ear. The patient was
asked to remain still in the supine position with their head
tilted 45 towards the opposite ear for at least 20minutes
and to refrain from swallowing to maintain perfusion of the
middle ear by the DXM.
Main outcome measurements
The final assessment of the patients was performed by evalu-
ating the PTA one month after the treatment, i.e. between 30
and 45 days after SNHL onset. In the IT Group, PTA assess-
ment was also performed before each transtympanic injec-
tion. The audiometric parameters used to assess the outcome
were: (1) hearing recovery, defined as (initial PTA) – (PTA at
day 30); (2) hearing recovery percentage calculated with the
following formula: ((initial PTA) – (PTA at day 30))/(initial
PTA) 100%. “Complete hearing improvement” was defined
as an improvement of more than 10 dB in PTA. Recovery
was considered complete when the final PTA was above
25 dB. If final recovery was under the 25 dB threshold, then
PTA improvement of 50% was considered “partial hearing
improvement”. “No recovery” was defined as an improve-
ment in PTA of equal or less than 10 dB regardless of PTA
improvement percentage being better than 50%. Each fre-
quency was also tested independently before and after treat-
ment. The following variables considered to influence
recovery were analyzed: age, sex, association with vertigo or
vestibular deficit on caloric testing, and audiometric pattern
of SNHL. Time between onset of SNHL and onset of treat-
ment, side effects, and subjective symptoms were
also recorded.
Statistical analysis
Quantitative variables were described as the
mean ± Standard Deviation (SD), and frequency distribution
tables were used for all categorical variables. A t-test was
performed to compare the improvement percentages
between IT and CONTROL groups for each SNHL pattern.
A v2 test was used to compare the percentages of hearing
recovery in each group. The Mann–Whitney U-test and
Fisher t-test were performed to evaluate the auditory gain
before and after treatment for each frequency and SNHL
type. All tests were carried out based on two-tailed analysis,
p< .05 was considered to indicate a statistically signifi-
cant difference.
Results
Population
Patients’ baseline characteristics according to sex, affected
ear, and pattern of initial audiogram are presented in
Table 1. The mean ages of the patients were 50.9 and 50.3
years for the IT and control groups, respectively. The mean
intervals from hearing loss onset to i.v. treatment adminis-
tration were 11.8 and 8.1 days for the IT and control
groups, respectively. There were no statistically significant
differences between the two groups with regard to age, time
to admission, mean PTA before and after first-line intraven-
ous treatment, and audiometric patterns of ISSNHL (Table
2). Audiogram type E was less frequent in the control group
when compared with the IT group but this difference was
not statistically significant. For all patients, tinnitus was pre-
sent in 77% of the patients, vertigo in 22% of the patients,
hypertension in 17% of the patients, and diabetes mellitus
in 6% of the patients, with no significant differences
between the groups.
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Table1. Patients’ baseline characteristics according to sex, site of affected ear,
and shape of initial audiogram.
Control group (n¼ 255) IT group (n¼ 84) p value
Sex: Male/Female 62% (158)/38% (97) 57% (48)/43% (36) .52
Affected ear: Right/Left 58% (147)/42% (108) 62% (52)/38% (32) .58
Shape A 15% (38) 11% (9) .49
Shape B 25% (65) 26% (22) .96
Shape C 20% (52) 14% (12) .35
Shape D 11% (29) 5% (4) .14
Shape E 27% (71) 44% (37) .07
Table 2. Mean PTA according to each type of ISSNHL after 7 days of IV ster-
oid treatment.
PTA (dB) IT group Control group p value
Type A 42.4 ± 17 (9/84) 45.3 ± 20 (38/255) .79
Type B 59.4 ± 21 (22/84) 58.3 ± 25 (65/255) .96
Type C 57.6 ± 21 (12/84) 53.7 ± 23 (52/255) .99
Type D 68.4 ± 26 (4/84) 63.3 ± 31 (29/255) .99
Type E 101.3 ± 21 (37/84) 98.3 ± 25 (71/255) .83
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Audiometric assessment after 7-day intravenous
steroid treatment
After the initial i.v. steroid treatment, there was no signifi-
cant difference between the IT group and the Control group
in terms of mean PTA, which made the groups comparable.
All patients had severe hearing loss, with a mean PTA of
78 dB in both groups (77 ± 29 dB and 78 ± 35 dB in the
Control group and the IT group, respectively). Statistical
analysis did not indicate any significant difference between
the two groups for each audiogram pattern (Table 2).
Hearing outcome after treatment completion
(Intratympanic group vs Control group)
Table 3 summarizes the audiometric results after treatment
completion for the IT group and the Control group at one
month. As for the main outcome measure, there was no sig-
nificant difference in terms of hearing recovery between the
groups; the average hearing improvement was 26.5 dB for
the IT group and 27.9 dB for the Control group (p¼ .67).
There were no significant differences between the groups
for the other variables. In the Control group, 29.0% (74/
255) of the patients had complete hearing recovery, and in
the IT group, 22.6% (19/84) of the patients had complete
hearing recovery (p¼ .32). At day 30, 42% of the Control
group (106/255) and 36% of the IT group (30/84) showed a
partial hearing recovery (dB) PTA improvement of 50%
(p¼ .41). With regard to the patients who did not recover
their hearing (improvement <10 dB), there was no differ-
ence between the IT group and the Control group (p¼ .84).
Similar non-significant results were observed when evaluat-
ing hearing recovery >15 dB after one month for the IT
group and the Control group (p¼ .32). Table 4 shows the
percentage of complete recovery for each audiogram pattern
of both groups. Table 5 shows a comparison of the two
groups according to each frequency tested and each audio-
gram pattern; this table indicates that patients who had a
type E audiogram (total deafness) and received IT steroid
treatment showed a statistically significant improvement in
hearing recovery at 1000, 2000, and 4000Hz when com-
pared with control patients. Hearing recovery was 50.4 dB vs
41.6 dB at 500Hz (p¼ .17), 49.1 dB and 35.3 dB at 1000Hz
(p¼ .02), 45.1 dB vs 31.4 at 2000Hz (p¼ .03), and 37.1 dB
vs 25.1 dB at 4000Hz (p¼ .05) in the IT group versus the
Control group, respectively (Table 4). When all hearing loss
types were combined, the mean PTA recovery between IT
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Table 3. Main outcome measurements of hearing in Control group and IT group.
Control group IT group p value
Complete hearing recovery (dB). final PTA <25 dB at day 30 29.0% (74/255) 22.6% (19/84) .32
Partial hearing recovery (dB) PTA improvement of 50% at day 30 42% (106/255) 36% (30/84) .41
Average hearing improvement (dB) after 30 days 27.9 26.5 .67
Hearing improvement >15 dB after 30 days 63% (160/255) 56% (47/84) .32
No recovery¼ hearing improvement <10dB 30% (77/255) 32% (27/84) .84
Table 4. Percentage of complete recovery for each audiogram pattern of both groups..
Type A Type B Type C Type D Type E
IT group (19 pts) 21% (4pts) 15.8% (3pts) 15.8% (3pts) 15.8% (3pts) 31.5% (6pts)
Control group (74 pts) 24.3% (18pts) 17.5% (13pts) 18.9% (14pts) 16.2% (12pts) 22.9% (17pts)
Type A: low tone; Type B: flat; Type C: high tone; Type D: cup-shaped; Type E: total or subtotal
Table 5. Hearing improvement for each audiogram type (A, B, C D and E) at 500, 1000, 2000 and 4000 hz at one month for the IT group
and Control group.
Hz Type A Type B Type C Type D Type E
500 IT group 31.0 ± 29 27.3 ± 33 41.5 ± 35 61.3 ± 17 50.4 ± 33
500 Control group 33.1 ± 22 20.6 ± 27 19.3 ± 17 24.8 ± 32 41.6 ± 29
p value 500 Hz .79 .35 .005 .04 .17
1000 IT group 19.5 ± 25 26.5 ± 32 32.5 ± 40 56.3 ± 17 49.1 ± 34
1000 Control group 28.7 ± 22 23.4 ± 29 25.9 ± 22 30.2 ± 35 35.3 ± 26
p value 1000 Hz .24 .68 .47 .17 .02
2000 IT group 17.5 ± 19 20.6 ± 28 30 ± 37 42.5 ± 13 45.1 ± 36
2000 Control group 22.6 ± 22 23.1 ± 28 28 ± 23 26.4 ± 32 31.4 ± 25
p value 2000 Hz .49 .73 .82 .34 .03
4000 IT group 10.5 ± 18 16.5 ± 27 22.0 ± 39 23.8 ± 5 37.1 ± 32
4000 Control group 13.1 ± 16 14.2 ± 25 17.4 ± 21 19.5 ± 27 25.1 ± 27
p value 4000 Hz .65 .73 .59 .76 .05
All frequencies IT group 19.6 ± 21 22.7 ± 28 31.5 ± 36 45.9 ± 11 45.5 ± 31
All frequencies Control group 24.4 ± 19 41.3 ± 25 22.6 ± 17 25.2 ± 29 33.4 ± 24
p value .47 .72 .25 .18 .03
Hearing improvement in dB according to each audiogram type.
For audiogram type A IT group n¼ 9/84 versus Control group n¼ 38/255.
For audiogram type B IT group n¼ 22/84 versus Control group n¼ 65/255.
For audiogram type C IT group n¼ 12/84 versus Control group n¼ 52/255.
For audiogram type D IT group n¼ 4/84 versus Control group n¼ 29/255.
For audiogram type E IT group n¼ 37/84 versus Control group n¼ 71/255.
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and Control groups was found to be significantly different
(34.1 dB vs 25.8 dB respectively with p¼ .01).
Side effects
Two patients had a persistent pinpoint perforation three
months after the treatment. One patient recovered spontan-
eously, and the second patient’s condition was resolved in
six months post-treatment after placement of a tympanic
paper patch. Eight patients in the IT group experienced ver-
tigo while being injected, but their symptoms resolved
themselves within 1min. One subject experienced a worsen-
ing of hearing of approximately 10 dB. This patient had an
initial PTA of 103 dB. After treatment, the patient recovered
hearing to 72 dB.
Discussion
The most frequently suggested theories as to the cause of
ISSNHL include viral infection, inflammatory or immune-
mediated reactions, and vascular insufficiency.
Owing to the differences in etiopathogenesis of ISSNHL,
different therapeutic agents have been proposed including
carbogen therapy, anticoagulants, antiviral agents, and
hyperbaric therapy alone or in association with drugs [2].
One of the most accepted treatment choices is systemic ster-
oid therapy but it is not always feasible due to the pre-exist-
ing conditions of patients (hypertension, diabetes, glaucoma,
severe heart conditions, severe ulcers, hemorrhagic disor-
ders, and renal failure). The IT route has two advantages: it
allows a higher concentration of the drugs in the perilymph,
and it minimizes the risk of systemic side effects.
Nevertheless the pharmacokinetics of the drugs and their
effects on the inner ear are still unclear [9]. Most studies
have shown the benefits of IT steroids in the treatment of
ISSNHL in patients in whom previous systemic therapy had
failed [10]. The time between the onset of symptoms and
the beginning of therapy (delay) is between 0 and 15 days;
this is a common inclusion criterion in the literature
because after 15 days the efficacy of the therapy is signifi-
cantly reduced. Considering this early beginning of the ther-
apy it is possible that the evaluation of the short-term
efficacy could be influenced by spontaneous recovery. In a
recent randomized, triple-blind, placebo-controlled trial,
spontaneous recovery was shown to occur in 25% of
patients with flat curve [2].
This study aimed to compare auditory outcomes at one
month in a control group type study for patients with severe
to profound ISSNHL. To our knowledge, this is the largest
retrospective control group study reported for IT steroids
administered as a salvage treatment to patients with severe
to profound ISSNHL. The main results of this study showed
no significant benefits from IT steroid treatment although
patients with total deafness did experienced a 45.5 ± 31 dB
gain depending upon frequency.
The present study suggests that IT steroid administration
is not effective as salvage treatment for patients with severe
ISSNHL; however, for a subgroup of patients with total
deafness, IT steroid treatment may improve hearing. Better
outcomes for patients with total deafness may be related to
the sample sizes within the IT group, when divided by type
of hearing loss. Patient groups with total deafness were rela-
tively small and may not be representative. In our study,
few side effects were reported, and tolerance of the treat-
ment was very good in the vast majority of patients.
Therefore, the benefit/risk ratio for patients with total deaf-
ness seems favorable, and IT steroid treatment could be
considered as a salvage treatment for patients experiencing
total deafness. Because steroids should diffuse through the
round window at the base of the cochlea that codes for high
frequencies, one might have thought that IT steroid treat-
ment would produce a beneficial effect for higher frequen-
cies. In our study, we did not find any favorable effects on
these frequencies to support this hypothesis.
Intracochlear drug concentrations depend on the time
the drug is in contact with the round window membrane
(RWM). In addition, significant basal to apical concentra-
tion gradients in the cochlea have been measured after local
drug application to the RWM, and there is increasing evi-
dence that the time of exposure of drugs to the RWM influ-
ences the basal-apical drug distribution [11]. Better
outcomes might have been expected for high frequencies
due to this basal-apical drug gradient and the frequency
tonotopy of the cochlea; however, this was not the case in
our study. Some researchers have advocated the need for
standardized techniques for the application of medications
through the RWM [11]. Kakehata et al. investigated daily
short-term IT dexamethasone administration using laser-
assisted myringotomy (LAM) for ISSNHL patients without
concurrent therapy; they reported a high response rate and
high cure rate, and this treatment proved to be an alterna-
tive therapeutic option to high-dose systemic steroids as a
first- and/or second-line treatment [12]. In addition, Park
et al. have shown that RWM vibration can enhance the
effect of intratympanic corticosteroid injection [13]. On the
basis of the available literature, it seems that topical steroids
can be a valuable solution for ISSNHL patients who either
cannot tolerate systemic steroid therapy or are refractory to
it [14,15], and some authors suggest a combination of intra-
tympanic and oral steroids [10–16]. The issue remains
whether IT steroid treatment may be a more beneficial
option as a primary treatment [17]. Some works suggest a
direct comparison of oral vs. IT corticosteroid showed no
difference in efficacy [18,19]. The possible pharmacokinetic
advantages of the continuous delivery of drugs to the RWM
must be weighed against the invasiveness of the therapy, the
time required, and the cost considerations associated with
this application strategy. Plontke et al. used an implanted
microcatheter to continuously deliver drugs to the RWM,
which demonstrated efficacy in restoring severe ISSNHL.
This application strategy appears feasible, but the limited
placebo-controlled observation period and the absence of
serious adverse events warrants further investigation for
local inner ear drug delivery as a first- or second-line treat-
ment option for ISSNHL [20].
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In conclusion, the results of the present study suggest
that IT steroid salvage treatment was not effective for
patients with severe ISSNHL, although patients with total
deafness seem to benefit from IT steroid treatment. Further
studies are required to address several issues with IT steroid
administration; namely, whether it can be used as a first-
line treatment instead of the intravenous treatment for
patients with ISSNHL.
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